Domača stranBMY • NYSE
add
Bristol-Myers Squibb Co
Prejšnji trg. dan.
45,59 $
Dnevni razpon
45,43 $ - 46,51 $
Letni razpon
42,52 $ - 63,33 $
Tržna kapitalizacija
94,19 mrd. USD
Povprečni obseg
18,65 mio.
Razm. P/E
15,62
Dividendna donosnost
5,36 %
Primarna borza
NYSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 12,22 mrd. | 2,77 % |
Stroški poslovanja | 5,05 mrd. | −26,13 % |
Čisti dohodek | 2,20 mrd. | 81,75 % |
Čista dobičkovnost prihodkov | 18,01 | 76,92 % |
Earnings per share | 1,63 | −9,44 % |
EBITDA | 4,91 mrd. | 1,38 % |
Efektivna davčna stopnja | 29,51 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 16,50 mrd. | 103,88 % |
Skupna sredstva | 96,89 mrd. | 3,44 % |
Skupne obveznosti | 78,29 mrd. | 2,38 % |
Celoten lastniški kapital | 18,60 mrd. | — |
Shares outstanding | 2,04 mrd. | — |
Razmerje P/B | 5,00 | — |
Donosnost sredstev | 10,07 % | — |
Donosnost kapitala | 13,97 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 2,20 mrd. | 81,75 % |
Denar iz dejavnosti | 6,31 mrd. | 12,88 % |
Denar iz naložb | −1,70 mrd. | −677,17 % |
Denar iz financiranja | −1,49 mrd. | 61,32 % |
Neto sprememba denarnih sredstev | 3,12 mrd. | 95,05 % |
Prost denarni tok | 4,26 mrd. | −23,81 % |
Vizitka
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Generalni direktor
Datum ustanovitve
1887
Sedež organizacije
Spletno mesto
Zaposleni
34.100
